Targets › CYP17A1
9 programs from 8 companies in 49 trials: 35 Phase 2, 7 Phase 3, 5 Phase 1, 2 Phase 4; Oncology; next expected readout Nov 2026.
A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. (UniProt, P05093)
Open in Phaseline: the race on CYP17A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Feb 2027 |
| Johnson & Johnson (Janssen) | Abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 3 | Prostatic Neoplasms; Prostate Cancer; Castration-Resistant Prostatic Cancer; Metastatic Prostate Cancer … | Nov 2027 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Abiraterone Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor | CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma … | Nov 2026 |
| University of Maryland, Baltimore | galeterone Androgen Receptor antagonist; Cytochrome P450 17A1 inhibitor | AR, CYP17A1 | Phase 2 | Advanced Pancreatic Cancer | Dec 2026 |
| Weill Medical College of Cornell University | Ketoconazole Cytochrome P450 51 inhibitor | CYP17A1 | Phase 2 | Prostate Cancer | Jun 2027 |
| Sun Pharmaceutical Industries | Abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 2 | Metastatic Cancer | Dec 2027 |
| Astellas | ASP5541 CYP17A1 inhibitor (17α-hydroxylase/17,20-lyase inhibitor); intramuscular depot formulation | CYP17A1 | Phase 2 | Prostate Cancer | Oct 2028 |
| St Vincent's Hospital, Sydney | Seviteronel Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist | CYP17A1, AR | Phase 1 | Triple Negative Breast Cancer | Dec 2027 |
| Astellas | PRL-02 injection Abiraterone decanoate - CYP17A1 inhibitor for testosterone reduction | CYP17A1 | Phase 1 | Prostate Cancer | May 2029 |
Prostate Cancer (14) Metastatic Prostate Cancer (3) Castration Levels of Testosterone (3) Metastatic Castration-resistant Prostate Cancer (3) Prostatic Neoplasms (2) Metastatic Prostate Carcinoma (2) Prostate Adenocarcinoma (2) Prostatic Neoplasms, Castration-Resistant (2) Castration-Resistant Prostatic Cancer (1) Neoadjuvant Therapy (1) Metastatic Prostate Adenocarcinoma (1) Prostate Cancer Metastatic Castration-Resistant (1)
small molecule (9)
Astellas (2) Johnson & Johnson (Janssen) (1) AstraZeneca (1) Weill Medical College of Cornell University (1) St Vincent's Hospital, Sydney (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Sun Pharmaceutical Industries (1) University of Maryland, Baltimore (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.